ClinicalTrials.gg
RecruitingNCT07573956RadiotherapyUpdated May 7, 2026

Trial Evaluating Hypo-fractionated Accelerated Versus Conventional Fractionated Adjuvant RT in Head & Neck Malignancies

A Phase 2/3 interventional study of Standard conventionally fractionated PORT and hypo-fractionated PORT in Squamous Cell Carcinoma Head and Neck Cancer (HNSCC), sponsored by All India Institute of Medical Sciences. Recruiting at 1 site in India. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-07.

Primary conditionSquamous Cell Carcinoma of Head and NeckRegistry: Head and Neck NeoplasmsReclassifiedWhy we changed it
Registry
Head and Neck Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Squamous Cell Carcinoma of Head and Neck
Why
  1. The study's listed conditions name Squamous Cell Carcinoma of Head and Neck, a narrower term within Head and Neck Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by All India Institute of Medical Sciences · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
369
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Squamous Cell Carcinoma of Head and Neck with a site in India — 12 open to participants now, 14 under way, 7 of them phase 3. Squamous Cell Carcinoma of Head and Neck · India.

Planned enrollment
14th of 31
369 · median 224
Started
2026
with 3 others
Phase 2/3
3 of 33
2 open now
Primary completion
2028-06
later than 6 of 13 live
Registered
31st of 33
by date
Lead sponsor
1 of 33
All India Institute of Medical Sciences

Among the 33 studies in Squamous Cell Carcinoma of Head and Neck with a site in India, this one is the 14th largest by planned enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2026, is one of 3 in phase 2/3, reaches primary completion later than 6 of the 13 other live ones, and was the 31st registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

12 of the 33 studies in Squamous Cell Carcinoma of Head and Neck with a site in India are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Squamous Cell Carcinoma of Head and Neck with a site in India, or all of them as a file.
02

Study summary

Hypo-fractionated radiotherapy reduces the OTT (overall treatment time) which may in turn reduce rapid accelerated repopulation of clonogenic cells during waiting period after surgery. If this holds true, there is a potential to achieve better loco-regional control in with PORT for HNSCC. There is a strong radiobiological and economic rationale for delivery hypo-fractionated radiotherapy in HNSCC. The HYPCON III trial will be aimed to reduce the number of fractions by 50% (30 fr to 15 fr)

Read the detailed description

The current standard radiotherapy regimen for squamous cell carcinomas of the head and neck in the post operative setting is 60-66Gy in 30-33# delivered in 6 weeks with 5 fractions delivered per week. The aim of this study is to test whether a resource sparing, 3weeks, 15 fraction course of hypo-fractionated radiotherapy is non inferior to the conventional fractionation regimen delivering 30 fractions over6 weeks of post operative radiotherapy (PORT). Hypofractionation is already the standard of care in the treatment of cancers like breast cancer which has evolved from 50 Gy in 25 # to 40 Gy in 15# and finally to 26Gy in 5 # with similar tumor control rates and toxicity profiles.

Hypofractionation has shown promising results in prostate, lung cancer and CNS tumors. Hypofractionation has been initially explored in palliative setting for HNSCC. Unlike 2 dimensional RT deliver, recent past has seen a rapid evolution of RT delivery techniques like 3-dimensional conformal radiotherapy (3D CRT), intensity modulated radiotherapy (IMRT), image guided radiotherapy (IGRT), volumetric arc therapy (VMAT). It is now possible to spare adjoining critical organs at risk which make delivery of hypo-fractionated feasible for HNSCC. Recently, the IAEA multicentric trial in radical setting for HNSCC has proved equivalent results in term of both disease control and toxicity with delivery of hypo-fractionated RT. Shorter treatment time is more convenient to the patient. The reduction in the number of fractions required per patient will help in optimal unitization of radiotherapy resources, especially in a low/moderate income country like India where the burden of cancer hugely surpasses the resource availability. Hypo-fractionated schedules have potential to provide attractive cost benefits.

03

Conditions studied

  • Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)

Browse trials for

04

In context

Squamous Cell Carcinoma of Head and Neck Reclassified

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

This study's planned enrollment of 369 is above the median of 48 across 1,657 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Lead sponsor

All India Institute of Medical Sciences is the lead sponsor of 27 studies on the registry; 18 are open to participants now.

Compared within Squamous Cell Carcinoma of Head and Neck, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Head and Neck Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with pT1-4 squamous cell carcinoma of oral cavity/ oropharynx/ larynx/ hypopharynx with any of the intermediate risk features:

    • Positive lymph node (s)
    • Perineural invasion
    • Lympho-vascular invasion
    • Close margins
  • Age 18-80yrs
  • performance status 0-1at time of surgery
  • Available FOR long term follow-up

Exclusion criteria

Exclusion Criteria:

  • High risk factors following resection: positive-margin(s)and/or extra nodal extension (ENE)
  • pT1-2disease and no high-risk features (LVSI, PNI, Close margins,pN0)
  • Patients receiving or concurrent Chemotherapy
  • Non-Squamous Histology
  • Distant
  • Synchronous or second primary outside of the oropharynx, oral cavity, larynx and hypopharynx
  • Pregnant females or nursing mothers due to the probability of congenital anomalies and potential of this regimen to harm nursing infants.
  • Prior Radiotherapy to head and neck region
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
369 participants (estimated)

Study arms

  • Active comparator
    Standard conventionally fractionated PORT Arm A

    hypo-fractionated PORT Arm B

    Radiation: Standard conventionally fractionated PORT

  • Experimental
    Hypo-fractionated PORT Arm B

    Hypo-fractionated PORT Arm B

    Radiation: hypo-fractionated PORT

Interventions

  • RadiationStandard conventionally fractionated PORT

    60Gy in 30 fractions over 6 weeks (5 fractions per week)

  • Radiationhypo-fractionated PORT

    4Gy in 15 fractions over 3 weeks (5 fractions per week)

07

What researchers measure

Primary outcomes

  1. loco-regional control at 24 months

    Time frame: 24 months

Secondary outcomes

  1. swallowing function

    using MD Anderson Dysphagia Inventory pre RT, post RT, 3, 6, 12, 18, 24 months

    Time frame: 2 years

  2. Disease free survival

    longitudinal assessment every 3, 6, 12, 18, 24 months

    Time frame: 2 years

  3. Overall survival

    longitudinal assessment every 3, 6, 12, 18, 24 months

    Time frame: 2 years

  4. Quality of life EORTC QLQ C30

    EORTC QLQC30 module \[longitudinal assessment at 3, 6, 12, 18 and 24 months\] The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items. Each of the multi-item scales includes a different set of items - no item occurs in more than one scale. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. High score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.

    Time frame: 2 years

  5. Quality of life H&N 35

    EORTC H\&N 35 module \[longitudinal assessment at 3, 6, 12, 18 and 24 months\] The head \& neck cancer module incorporates seven multi-item scales that assess pain, swallowing, senses (taste and smell), speech, social eating, social contact and sexuality. There are also eleven single items. For all items and scales (maximum score 100 and minimum score 0), high scores indicate more problems (i.e. there are no function scales in which high scores would mean better functioning). The scoring approach for the QLQ-H\&N35 is identical in principle to that for the symptom scales / single items of the QLQ-C30.

    Time frame: 2 years

  6. RTOG Acute Toxicity Post Radiation therapy

    Acute toxicity is the side effects that appear within 90 days after the radiation therapy and will be assessed using RTOG acute toxicity scale with grading from 0 to IV where 0 represents no findings and IV being the worst Findings. Higher values will be showing worsening of the condition. it will be scored weekly during radiation.

    Time frame: 90 days

  7. RTOG Late toxicity post radiation therapy

    late toxicity is the side effects that appear after 90 days following the radiation therapy and will be assessed using RTOG Late Radiation Morbidity Grading (Radiation Therapy Oncology Group) with maximum value of 4 showing very severe / disabling and minimum value of 0 showing no toxicity. Higher values will be showing worsening of the condition. longitudinal assessment will be done every 3, 6, 12, 18, 24 months

    Time frame: 2 years

  8. Late Toxicity using LENT- SOMA scale

    using the Late effects in normal tissues- subjective, objective, management, analytic (LENT SOMA) scale. assessment will be done at 3-, 6-and 12 months posttreatment.

    Time frame: 12 months

08

Study locations

1 of 1 sites recruiting
  • Dr. Aman Sharma, Associate Professor, Radiation Oncology, NCI, AIIMS
    Jhajjar, Haryana, India
    Recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Jun 2028, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2026
First posted
May 7, 2026
StartActual
Feb 10, 2026
Primary completionEst.
Jun 30, 2028
CompletionEst.
Dec 30, 2028
Last update
May 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07573956
Lead sponsor
All India Institute of Medical Sciences
Collaborators
Indian Council of Medical Research
Responsible party
Aman Sharma (Associate Professor, All India Institute of Medical Sciences) — Principal investigator
First posted
May 7, 2026
Start date
Feb 10, 2026
Primary completion
Jun 30, 2028 (estimated)
Completion
Dec 30, 2028 (estimated)
Last update
May 7, 2026

Study contacts

Dr. Aman Sharma
Contact
amans757@gmail.com
+917018529339
Dr. Aman Sharma
principal investigator · National cancer Institute, AIIMS, Jhajjar

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion